Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.

View Full Paper
Ask AI
Bookmark
Share

Authors

JZJin ZhouUnion HospitalTYTao YouFujian University of Traditional Chinese MedicineYWYun WangObstetrics and Gynecology Hospital of Fudan University

Discussion

Loading...

Member takes

Implication

Single-center study shows high safety and efficacy of glofitamab bridging therapy in large B-cell lymphoma, indicating its potential as a pre-CAR-T treatment.

Key Points

  • Glofitamab achieved a 75% overall response rate in patients with large B-cell lymphoma prior to CAR-T therapy.
  • Before CAR-T therapy, results included 25% complete response and 42% partial response in evaluable patients.
  • Assessment using historical patient data highlighted manageable safety with low discontinuation rates due to adverse events.
  • This treatment leads to significant progression-free survival, emphasizing its role in bridging to effective therapies.

Cite This Study

Zhou et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4fahttps://doi.org/10.1182/blood-2025-7256
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL2025 · 1 citations
  2. 2Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab2025
  3. 3Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma2025
  4. 4Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL2025
  5. 5Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma2025 · 1 citations